Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alma Fulurija

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 26, 2023
Safety of Streptococcus pyogenes Vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing MonitoringEdwin J Asturias, Jean-Louis Excler, James Ackland, et al.
Clinical Case Reports|November 11, 2016
<i>Helicobacter pylori</i> overcomes natural immunity in repeated infectionsBjörn Stenström, Helen M Windsor, Alma Fulurija, et al.
The Journal of Infectious Diseases|March 12, 2024
Nasal Delivery of Haemophilus haemolyticus Is Safe, Reduces Influenza Severity, and Prevents Development of Otitis Media in MiceNaomi Scott, Kelly M Martinovich, Caitlyn M Granland, et al.
Open Forum Infectious Diseases|September 21, 2022
Standardization of Epidemiological Surveillance of Group A Streptococcal Pharyngitis<sup></sup>Kate M Miller, Robert R Tanz, Stanford T Shulman, et al.
Journal of Hypertension|December 5, 2006
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicityPatrice M Ambühl, Alain C Tissot, Alma Fulurija, et al.
Antimicrobial Agents and Chemotherapy|May 20, 2025
Population pharmacokinetics of penicillin G: insights into increased clearance at low concentrations to guide development of improved long-acting formulations for syphilis and prevention of rheumatic feverOkhee Yoo, Sam Salman, Thel K Hla, et al.
The Lancet. Microbe|March 29, 2025
Establishing the lowest penicillin concentration to prevent pharyngitis due to Streptococcus pyogenes using a human challenge model (CHIPS): a randomised, double-blind, placebo-controlled trialThel K Hla, Joshua Osowicki, Julie A Marsh, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 26, 2023
Safety of Streptococcus pyogenes Vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing MonitoringEdwin J Asturias, Jean-Louis Excler, James Ackland, et al.
Clinical Case Reports|November 11, 2016
<i>Helicobacter pylori</i> overcomes natural immunity in repeated infectionsBjörn Stenström, Helen M Windsor, Alma Fulurija, et al.
The Journal of Infectious Diseases|March 12, 2024
Nasal Delivery of Haemophilus haemolyticus Is Safe, Reduces Influenza Severity, and Prevents Development of Otitis Media in MiceNaomi Scott, Kelly M Martinovich, Caitlyn M Granland, et al.
Open Forum Infectious Diseases|September 21, 2022
Standardization of Epidemiological Surveillance of Group A Streptococcal Pharyngitis<sup></sup>Kate M Miller, Robert R Tanz, Stanford T Shulman, et al.
Journal of Hypertension|December 5, 2006
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicityPatrice M Ambühl, Alain C Tissot, Alma Fulurija, et al.
Antimicrobial Agents and Chemotherapy|May 20, 2025
Population pharmacokinetics of penicillin G: insights into increased clearance at low concentrations to guide development of improved long-acting formulations for syphilis and prevention of rheumatic feverOkhee Yoo, Sam Salman, Thel K Hla, et al.
The Lancet. Microbe|March 29, 2025
Establishing the lowest penicillin concentration to prevent pharyngitis due to Streptococcus pyogenes using a human challenge model (CHIPS): a randomised, double-blind, placebo-controlled trialThel K Hla, Joshua Osowicki, Julie A Marsh, et al.
Pageof 3